International Journal of Hematology

DOI: 10.1007/s12185-013-1294-z Pages: 333-344

Current approaches for the treatment of multiple myeloma

1. Saitama Medical University, Division of Hematology, Saitama Medical Center

Correspondence to:
Reiko Watanabe
Email: reikow@saitama-med.ac.jp

Close

Abstract

The development of novel therapeutic agents over the past decade, including the proteasome inhibitor, bortezomib, and the immunomodulatory drugs, lenalidomide and thalidomide, has resulted in improved outcomes for patients with multiple myeloma. However, there is still considerable controversy as to which regimen should be used as first-line therapy, which patients should be considered for autologous or allogeneic transplantation, and how consolidation or maintenance therapy is used in patients that have a good response to first-line therapy. The present paper will review clinical evidence from previous and ongoing studies to explore issues related to these questions.

This article is freely available, click here to access the full text/PDF

Share the Knowledge